The rise and fall of beta-agonists in the treatment of ARDS

Critical Care, 04/10/2012

The ALTA trial was terminated on the grounds of futility after it became clear that salbutamol did not affect ventilator–free days. The BALTI–2 trial was terminated for similar reasons alongside concerns about safety and tolerability. Together these findings suggest that the routine administration of β–agonists as a treatment for acute respiratory distress syndrome (ARDS) should be avoided.

Print Article Summary Cat 2 CME Report